Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12
Altimmune management will host a conference call at
Conference Call Information:
|International Dial-in:||(203) 518-9708|
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Investor and Media Contact:
Chief Financial Officer
Source: Altimmune, Inc